Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy

Therapeutic Drug Monitoring

Volumn 29, Issue 4, 2007, Pages 391-398

  Mendonza, Anisha E ^a   Zahir, Hamim ^a   Gohh, Reginald Y ^b   Akhlaghi, Fatemeh ^a,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Abbreviated AUC; Diabetes; Limited sampling strategy; Pharmacokinetics; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MALE; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEADY STATE; STOMACH EMPTYING; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; GASTRIC EMPTYING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; SAMPLING STUDIES; TACROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 34547687359     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811f319b     Document Type: Article

References (36)

1. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56:23-46.
2. Jiang H, Suguo H, Takahara S, et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplant Proc. 1991;23:2933-2936.
3. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 2003;75:2048-2053.
4. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
5. van Hooff JP, Boots JM, van Duijnhoven EM, et al. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc. 1999;31:54S-57S.
6. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623-653.
7. van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25:707-712.
8. Wallemacq PE, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 1998;23:367-370.
9. Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant. 2005;5:1383-1391.
10. Prescott WA Jr, Callahan BL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy. 2004;24:532-537.
11. Centers for Disease Control and Prevention. Incidence of end-stage renal disease among persons with diabetes - United States, 1990-2002. MMWR Morb Mortal Wkly Rep. 2005;54:1097-1100.
12. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-185.
13. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477-490.
14. Cashion AK, Holmes SL, Hathaway DK, et al. Gastroparesis following kidney/pancreas transplant. Clin Transplant. 2004;18:306-311.
15. van Duijnhoven E, Christiaans M, Undre N, et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc. 1998;30:1268-1270.
16. van Duijnhoven E, Christiaans M, Schafer A, et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc. 1998;30:1266-1267.
17. Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit. 2006;28:95-101.
18. Zahir H, Akhlaghi F. Development and validation of a rapid LC-MS/MS technique for simultaneous determination of CsA and TAC in human blood. The AAPS Journal. 2004;6:M1017.
19. Center for Drug Evaluation and Research, US Food and Drug Administration. Bioanalytical Method Validation; Guidance for Industry 2001. Available at: www.fda.gov/cder/guidance/4252fnl.htm. Accessed January 1, 2007.
20. Faulk JS. Diabetes control and education in transplant care improves outcomes. Nephrol News Issues. 2006;20:36, 39, 41.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
22. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-160.
23. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol. 2004;15(Suppl 1):S25-S29.
24. Horowitz M, Edelbroek M, Fraser R, et al. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance, and treatment. Scand J Gastroenterol. 1991;26:673-684.
25. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:151-159.
26. Sanaka M, Koike Y, Yamamoto T, et al. A reliable and convenient parameter of the rate of paracetamol absorption to measure gastric emptying rate of liquids. Int J Clin Pharmacol Ther. 1997;35:509-513.
27. Kuypers DR, Claes K, Evenepoel P, et al. The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. Drug Metab Dispos. 2004;32:1421-1425.
28. Mekki Q, Lee CC, Carrier S. The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients [Abstract]. Clin Pharmacol Ther. 1993;53:229.
29. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part I). Clin Pharmacokinet. 1990;19:147-159.
30. Zahir H, Nand RA, Brown KF, et al. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46:27-35.
31. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17:606-614.
32. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419-430.
33. Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit. 2005;27:431-434.
34. Stolk LML, van Duijnhoven EM, Christiaans MHL, et al. Evaluation of prediction of tacrolimus area under the curve by trough concentrations. Br J Clin Pharmacol. 2001;53:543P-559P.
35. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35:660-666.
36. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43:741-762.